News

Fierce Biotech2d
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...
NJBIZ1d
Sanofi’s $130M Morristown flagship puts people first
Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.
PharmTech1d
Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline
Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...
US Approves GSK’s Lung Disease Drug, Fueling Rivalry With Sanofi
GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.
Medical Dialogues19h
Sanofi Gets CDSCO Panel Nod to Update Aldurazyme Prescribing Information
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to ...
BioSpace1d
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
Sanofi Redefines R&D strategy with AI: Vanguards of Health Care
Houman Ashrafian, Head of R&D at Sanofi. In this episode, Ashrafian joins Bloomberg Intelligence analyst Sam Fazeli to unpack how AI-powered portfolio construction, franchise-based innovation and a ...
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of ...